Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The ROADMAP project launches its Data Cube. The Cube offers a dynamic overview of the ‘landscape’ of data availability in Europe for Alzheimer’s disease research.

Funded through the Innovative Medicines Initiative, the public-private Real world outcomes across the Alzheimer's Disease spectrum for better care: Multi-modal data Access Platform (ROADMAP) project brought together 26 organisations led by Novartis and coordinated by the University of Oxford.

One of the partnership's main aspirations was to support the identification and integration of realworld data across multiple sources and countries. Through that, it intended to support opportunities for the development of evidence for the reimbursement and access of new technologies for the treatment of Alzheimer's disease (AD), ultimately aiming to drive healthcare systems towards better care and data capture.

The consortium therefore collaboratively developed this 3D 'heat map' assessment. It allows the visualisation of the different data sources and how they are able to capture different AD-outcomes together with their relevance for the different disease stages. Users can switch between the perspectives of people with dementia, carers and health professionals. Enabling the visualisation of the AD-related data availability in different types of European data
sources and the intrinsic gaps, has proven to be a powerful tool for the design, planning and validation of the models and strategies used to guide future recommendations to enhance AD research.

Through these efforts, ROADMAP helps address the challenge of how best to inform clinical and health-policy decisions by studying how to build a population-based integrated data environment and enabling its visualisation. The online version of the Data Cube is available here: https://datacube.roadmap-alzheimer.org.

The Data Cube is an important outcome of the ROADMAP project as it provides a much needed, overarching picture of priority outcomes, across the disease stages, and whether data is available. It helps to identify gaps in the evidence and provides a useful tool for regulatory and HTA purposes. - Dr Jacoline Bouvy, Senior Scientific Adviser, NICE

Similar stories

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.

Testing for hearing loss could 'reduce dementia risk' later in life

Research by Sarah Bauermeister of Dementias Platform UK into hearing loss and its impacts on the progress of dementia in later life has featured in extensive media coverage of a Brain Health Check-In tool created by Alzheimer's Research UK.

Factors influencing cognitive development - new longitudinal study

Data comes from more than 2,600 individuals from four different countries and looks at links between factors like childhood stature, IQ and schooling.

Director of MRC Brain Network Dynamics Unit appointed

From 2 January 2023, Professor Peter Magill will lead the Medical Research Council Brain Network Dynamics Unit (MRC BNDU) at the University of Oxford.

Raised intracellular chloride levels underlie the effects of tiredness in cortex

A new study, co-authored by Professor Vladyslav Vyazovskiy, published in Nature Neuroscience, has revealed that intracellular chloride levels within cortical pyramidal neurons reflect sleep–wake history.

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.